SCHEMBL29284933

SCHEMBL29284933

NS(=O)(=O)c1ccn(C[C@@H]2CCO2)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.33
▸ KDM4E B2RXH2 4/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ CA12 O43570 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ ALDH1A1 P00352 7/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ CASP7 P55210 1/20 0.32
▸ POLB P06746 1/20 0.31
▸ HPGD P15428 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29284936 1.00 TSHR (0.33) TSHRKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL22497240 0.93 KDM4E (0.42) TSHRKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL30366107 0.81 CA1 (0.44) CA12CA1CA2CA9ALDH1A1
SCHEMBL22497280 0.79 KDM4E (0.36) KDM4ECYP1A2CYP2C9CYP2C19CA12
SCHEMBL29284959 0.79 CA2 (0.39) CA12CA1CA2CA9MEN1
SCHEMBL23294075 0.74 CA1 (0.32) CA1CA2CA9
SCHEMBL20757841 0.74 CA1 (0.32) CA1CA2CA9
SCHEMBL20757429 0.73 CA1 (0.32) CA12CA1CA2CA9
SCHEMBL22524842 0.73 KDM4E (0.37) TSHRKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL23294078 0.72 HTR6 (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400561-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-12-05 — — US disclosed
EP-4408843-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY Viva Star Biosciences (Suzhou) Co., Ltd. (CN) 2024-08-07 — — EP disclosed
CN-118251393-A Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity 唯久生物技术(苏州)有限公司 2024-06-25 — — CN disclosed
WO-2023056264-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2023-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400561-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1B, IL1A, IL18 TSHR 3751/4885KDM4E 3870/4885CYP1A2 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback